FCGR2A and inflammatory bowel disease: Because undesired activation by autoantibodies contributes to the pathogenesis of various chronic inflammatory disorders, targeting of FcγR-TLR signaling may be a valuable tool to suppress inflammation in diseases such as RA, systemic lupus erythematous (SLE), and inflammatory bowel disease (IBD).